BiotechTube

Enzastaurin + Placebo

Phase 3Active
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Vascular Ehlers-Danlos Syndrome

Conditions

Vascular Ehlers-Danlos Syndrome

Trial Timeline

Jan 1, 2025 → Mar 1, 2027

NCT ID
NCT05463679

About Enzastaurin + Placebo

Enzastaurin + Placebo is a phase 3 stage product being developed by Aytu BioScience for Vascular Ehlers-Danlos Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT05463679. Target conditions include Vascular Ehlers-Danlos Syndrome.

What happened to similar drugs?

20 of 20 similar drugs in Vascular Ehlers-Danlos Syndrome were approved

Approved (20) Terminated (1) Active (0)
✅Rosuvamibe + MonorovaYuhanApproved
✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
✅Rosuvamibe + MonorovaYuhanApproved
✅Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
✅donepezil hydrochloride (Aricept)EisaiApproved
✅Lorcaserin hydrochloride + PlaceboEisaiApproved
✅Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05463679Phase 3Active

Competing Products

20 competing products in Vascular Ehlers-Danlos Syndrome

See all competitors
ProductCompanyStageHype Score
polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
37
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
22
CLS-AX + AfliberceptClearside BiomedicalPhase 2
25
Eylea + ALT-L9AlteogenPhase 1
29
Dulaglutide + PlaceboEli LillyPhase 3
40
raloxifene + placeboEli LillyPhase 3
40
EvacetrapibEli LillyPhase 1
29
Orforglipron + PlaceboEli LillyPhase 3
47
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
25
Prasugrel (CS-747) + ClopidogrelEli LillyPhase 2
35
Rosuvamibe + MonorovaYuhanApproved
39
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
43
Rosuvamibe + MonorovaYuhanApproved
43
olmesartanDaiichi SankyoPre-clinical
26
DS-7080a + RanibizumabDaiichi SankyoPhase 1
29
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
43
Avacincaptad PegolAstellas PharmaPhase 1
29
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
27
LexiscanAstellas PharmaPhase 2
35
YM872 (zonampanel)Astellas PharmaPhase 2
35